Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner [Yahoo! Finance]
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
AUSTIN, Texas May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of the Company's co-founder, President, Chairman and Chief Executive Officer (CEO), Rodney Varner , due to sudden complications after a courageous battle with cancer. Mr. Varner co-founded Genprex in 2009, and he has served on the Company's board of directors since 2012. He has served as President and CEO of Genprex since 2016. Under Mr. Varner's leadership, Genprex became a publicly traded company in 2018 and has successfully completed two Phase 1 clinical trials, opened three additional clinical trials, expanded its intellectual property portfolio, exclusively licensed new novel gene therapy technologies and has received three U.S. Food and Drug Administration Fast Track Designati
Show less
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex, Inc. (NASDAQ: GNPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Genprex dosing subjects in trial of combination therapy for small-cell lung cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerPR Newswire
- Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors [Yahoo! Finance]Yahoo! Finance
GNPX
Earnings
- 8/21/23 - Miss
GNPX
Sec Filings
- 5/15/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/29/24 - Form ARS
- GNPX's page on the SEC website